A robot at the operating table
Midwife, a dream job
My 50 years of dialysis
In battle against the coronavirus
An almost irreplaceable organ
Living life to the fullest with dialysis
Growing up with parenteral nutrition
Paul, the four-legged therapist
The History of Dialysis
Serving patients in Swaziland
"I want to help others, so they won’t give up"
From a local pharmacy to a global corporation
Group Outlook 2021
For FY/21, Fresenius projects sales growth1 in a low to mid-single-digit percentage range and at least broadly stable net income2,3 year-over-year, both in constant currency.
COVID-19 assumptions for guidance 2021
COVID-19 will continue to impact Fresenius’ operations in 2021. Current burdens and constraints caused by COVID-19 are expected to recede only in H2/21. The expected improvement in the Group’s relevant business environment from H2/21 is heavily dependent on continuously increasing levels of vaccination coverage in Fresenius’ relevant markets. These assumptions are subject to considerable uncertainty.
Fresenius closely monitors the development of COVID-19 case numbers, and the associated various containment measures being enacted in many of the Company’s relevant markets. A possible significant deterioration of the situation associated with further containment measures that could have a significant and direct impact on the health care sector without any appropriate compensation is not reflected in the Group’s FY/21 guidance.
